Press release
Olea Medical and Vital Partner to Provide Expanded Neuro MR Capabilities
Marseille, April 23rd, 2012 — Olea Medical, a provider of advanced MR and CT perfusion imaging post-processing and Vital, a Toshiba Medical Systems Group Company and leading provider of advanced visualization and analysis solutions for healthcare providers, have partnered to provide integrated thin-client advanced neurological MR (Magnetic Resonance) package. As part of the agreement, Olea’s MR solutions will be integrated on Vital’s VitreaAdvanced enterprise advanced visualization software..
“Olea Medical’s primary goal is to expand accessibility of its advanced neuro applications for patients’ benefit worldwide,” said Fayçal Djeridane, President and CEO at Olea Medical. “This partnership will serve as the foundation for providing a standardized platform for neuro MR studies, which enables more efficient patient care.”
The partnership will enable access throughout a hospital enterprise to advanced neuro MR capabilities through VitreaAdvanced software. Olea solutions provide clinicians with the ability to compute real-time perfusion and diffusion tensor maps, and review image series and maps for a fast and accurate diagnosis. Integrated with VitreaAdvanced, physicians are able to access advanced neuro MR imaging through a thin-client.
“Partnering with Olea supports Vital’s commitment to providing easy access to advanced clinical tools from anywhere,” said Erkan Akyuz, President of Vital Images. “Having access to advanced medical images is critical, particularly in neurological cases where time is of the essence. Enabling global access to an integrated neuro MR solution helps make that possible.”
About Olea Medical: Olea Medical designs and markets innovative perfusion imaging applications that significantly improve the diagnosis process. Olea Medical aims to become the leader in providing safe & accurate medical imaging software allowing physicians to make faster and improved diagnosis. PerfScape™ provides real-time computation of perfusion maps from raw MRI & CT data with unparalleled quality and accuracy. NeuroScape™ makes an instant multiparametric analysis of all series of images from scanners, and enables physicians to compute specific parameters required for an accurate diagnosis. Both PerfScape™ and NeuroScape™ are vendor agnostic and provide pathology-dedicated workflows.
For more information about Olea Medical, please visit www.olea-medical.com.
About Vital: Vital, a Toshiba Medical Systems Group Company, is a leading provider of advanced visualization and analysis software for physicians and healthcare specialists. The company's software provides users productivity and communication tools to improve patient care that can be accessed throughout the enterprise anytime, anywhere via the Web.
For more information, visit www.vitalimages.com.
Olea Medical to welcome Prof. Rachid Deriche, PhD, Research Director at Inria in the Sophia Antipolis - Mediterranee Research Center, as a member of its Scientific Advisory Board.
La Ciotat, France, April 5th, 2012 – Olea Medical, a provider of advanced MR and CT perfusion imaging post-processing, is pleased to announce that Prof. Rachid Deriche, PhD, Research Director at Inria in the Sophia Antipolis - Mediterranee Research Center, has recently joined its Scientific Advisory Board.
Prof. Rachid Deriche’s research interests are in Computational Imaging of the Central Nervous System (CNS - Brain and Spinal Cord), 3D Computer Vision and Mathematical Image Processing. More recently, he shifted his research interest from the domain of 3D Computer Vision to the domain of Computational CNS Imaging with a particular emphasis on the understanding and the processing of the CNS anatomical connectivity through Diffusion MRI and its combination with other modalities such as fMRI, MEG or EEG. More generally, Prof. Deriche is involved in the development and application of mathematical and computational imaging methods to help understand how the brain works and acquire a better understanding of its mechanisms.
Fayçal Djeridane, CEO of Olea Medical, declared: “We are very happy and honored to welcome Pr. Rachid Deriche as a member of our Advisory Board. He is a world-renowned leading expert in Computational CNS Imaging and an outstanding educator and researcher. I am persuaded that this collaboration will bring mutual benefits to both organizations but also support the development of new techniques that will benefit the medical community and ultimately patients suffering of some of the most devastating diseases”
“Olea Medical is a very dynamic and scientifically driven team that has acquired a significant expertise in perfusion imaging post-processing algorithms and methods and I welcome this opportunity to bring my extensive experience in the field of CNS Imaging to our collaboration” said Prof. Deriche. “Through this close collaboration, we are confident that we will achieve important breakthroughs to accelerate research and to facilitate improved health care.”
About Olea Medical: Olea Medical designs and markets innovative perfusion & diffusion ternsor imaging applications that significantly improve the diagnosis process. Olea Medical aims to become the leader in providing safe & accurate medical imaging software allowing physicians to make faster and improved diagnosis, thus saving lives. PerfScape™ provides real-time computation of perfusion maps from raw MRI & CT data with unparalleled quality and accuracy. NeuroScape™ makes an instant multiparametric analysis of all series of images from scanners, and enables physicians to compute all specific parameters required for an accurate diagnosis. Both PerfScape™ and NeuroScape™ are vendor agnostic and provide pathology-dedicated workflows. For more information about Olea Medical, please visit www.olea-medical.com.
About lnria : Established in 1967, Inria is the only public research body fully dedicated to computational sciences. Combining computer sciences with mathematics, Inria’s 3,400 researchers strive to invent the digital technologies of the future. Educated at leading international universities, they creatively integrate basic research with applied research and dedicate themselves to solving real problems, collaborating with the main players in public and private research in France and abroad and sharing the fruits of their work with innovative companies. The researchers at Inria published over 4,800 articles in 2010. They are behind over 270 active patents and 105 start-ups. In 2010, Inria’s budget came to 252.5 million euros, 26% of which represented its own resources.
SOFIRED contributes to the development of Olea Medical
Olea Medical is a SME specialized in the development of Medical Imaging software. This Company, created in July 2008, is considered today as the 63rd most promising company of France. (Source : L'express magazine : http://lentreprise.lexpress.fr/gestion-entreprise/palmares-les-72-entreprises-les-plus-prometteuses-en-france_31145.html?xtor=EPR-11-[ENT_Zapping]-20111115–338772@181943659-20111115063842 )
Indeed, in three years, the Company is now composed of about thirty employees in France and in the United States of America.
The Headquarter is in La Ciotat (France) and the subsidiary in Boston (USA). Olea Medical has a versatile team of experienced business developers and brilliant engineers, who have more than 50 years of cumulative experience in the medical, military and aviation industries. Together, they have designed simple and efficient solutions, based on their proprietary patented and innovative technology.
During the last three years, Olea Medical has developed two software suites: PerfScapeTM and NeuroScapeTM, dedicated to the analysis of stroke and brain tumors. Olea Medical works closely with physicians to meet their needs perfectly.
Today, its solutions are worldly known and used by ones of the most prestigious medical imaging centers. An increased numbers of private and public institutions are equipped with Olea Medical’s technology, leading to a substantial growth of the Company turnover by 12 in one year.
Furthermore, Olea Medical works with 6 distributors (Italy, Thailand, Canada, Switzerland, Belgium, Netherland) and is discussing with other potential distributors (Korea, China, Turkey, Poland, Taiwan, India).
Finally, this SME created an endowment fund « Urgence AVC ». This endowment fund aims to inform and increase public awareness on Stroke, its symptoms and safety gesture.
Persuaded by the perspectives and potential of this Company on the years to come and convinced by the performance level of its products with the launch of a new workstation dedicated to other pathologies, Sofired follows and gives to Olea Medical a support loan to meet its objectives and increase its development.
Dr. Tanenbaum joins the Medical Advisory Board of Olea Medical
18th November, 2010 - New-York, US
Olea Medical is pleased to announce that Dr Lawrence N. Tanenbaum, M.D., FACR has joined its Medical Advisory Board.
Fayçal Djeridane, CEO of Olea Medical, declared: “We are very happy to welcome Dr. Tanenbaum as member of our Medical Advisory Board. Dr. Tanenbaum is a leading clinician, educator, and an outstanding integrator of leading-edge technology and advanced imaging techniques into productive clinical practice.”
Dr. Tanenbaum is an Associate Professor of Radiology and the Director of MRI, CT and Outpatient / Advanced Imaging Development at Mount Sinai School of Medicine in New York stated: “I am enthused to become a part of the team of Advisors that contribute to the continuing development of Olea's advanced visualization products for neurological MRI and CT ».
Focusing on the processing of perfusion imaging, Olea Medical offers efficient software solutions - PerfScape™ & NeuroScape™ - to make the evaluation of acute stroke and brain tumor easier.
Press contact : Marine Pagni
marine.pagni@olea-medical.com - +33 (0)4 42 71 24 20
The University Hospital Germans Trias i Pujol implements Olea Medical clinical software solutions
29th, October 2010 - Badalona, SPAIN
THE UNIVERSITY HOSPITAL GERMANS TRIAS I PUJOL (BADALONA, SPAIN) AND THE INSTITUTE OF DIAGNOSTIC IMAGING (IDI) ANNOUNCE THE ACQUISITION OF THE INNOVATIVE MR PERFUSION POST-PROCESSING STROKE DIAGNOSIS SUITE – PERFSCAPE™ & NEUROSCAPE™ - DESIGNED BY OLEA MEDICAL TO MAKE MORE ACCURATE AND FASTER DIAGNOSIS.
As the stroke reference center in Catalonia and the second user of PerfScape™ & NeuroScape™ in Spain, Germans Trias i Pujol and the IDI (Institute of Diagnostic Imaging, Dra. Sira Domènech, in charge of the Neuroimaging Departement) confirm their leadership in the neuroscience field by using the most advanced imaging technique.
FDA-cleared and CE marked, PerfScape™ & NeuroScape™ instantly display all perfusion and diffusion maps, and quantify infarcted and penumbral tissues in acute stroke patients with nominal input from users.
PerfScape™ & NeuroScape™ offer a fast and effective solution to stroke centers that wish to rely on MRI to evaluate and triage acute stroke patients.
Pr. Antoni Dávalos, head of the Department of Neurosciences at the Hospital Universitari Germans Trias i Pujol stated, "Olea Medical develops fast, accurate and easy tools that allow physicians to obtain never observed, up to now, results in the stroke post-processing field.”
Press contact : Marine Pagni
marine.pagni@olea-medical.com - +33(0)4 42 71 24 20
New partnership between UHCMC and Olea Medical USA
13th, July 2010 -
University Hospitals Case Medical Center (UHCMC) and Olea Medical USA partner to implement the innovative MR perfusion processing software - PerfScape™ & NeuroScape™ - to evaluate acute stroke and triage patients.
As a leader in neurocritical care and stroke, UHCMC uses the most advanced imaging technics, including PerfScape™ & NeuroScape™.
About Olea Medical Software solutions
An FDA-cleared MR perfusion software package, PerfScape™ & NeuroScape™ instantly displays all perfusion and diffusion maps, and quantifies infarcted and penumbral tissues in acute stroke patients with nominal input from the user.
PerfScape™ & NeuroScape™ offers a fast and effective solution to stroke centers that wish to rely on MRI to evaluate and triage acute stroke patients.
Press contact : Marine Pagni
marine.pagni@olea-medical.com - +33 (0)4 42 71 24 20
Olea Medical software, PerfScape™ and NeuroScape™, outperform its competitors in the preliminary results of a comparative study
28th, May 2010 - Barcelona, SPAIN
Olea Medical’s stroke diagnosis suite surpasses its main competitors in a comparative study conducted at the Center for Stroke Research Berlin that aims to evaluate four major post-processing software packages used for perfusion MRI assessment. The investigation, led by Prof. Fiebach and the Stroke MRI group, reveals considerable discrepancies between the different applications and highlights the superior performances of PerfScape™ & NeuroScape™.
The different software solutions are rated on the grounds of accuracy, speed, and automated AIF selection among others. Based on these criteria, Olea Medical’s stroke suite outperforms its competitors on the following criteria: calculation time, mismatch evaluation, artefacts, and user friendliness.
These results stand in the line of a series of scientific studies, including PerfScape™ & NeuroScape™ conducted by major stroke research centers worldwide (i.e. NIH/NINDS).
About Olea Medical Software solutions
FDA-cleared and CE marked,PerfScape™ & NeuroScape™ instantly display all perfusion and diffusion maps, and quantify infarcted and penumbral tissues in acute stroke patients with nominal input from users.
PerfScape™ & NeuroScape™ offer a fast and effective solution to stroke centers that wish to rely on MRI to evaluate and triage acute stroke patients.
Press contact : Marine Pagni
marine.pagni@olea-medical.com - +33 (0)4 42 71 71 62
The University Hospital of Vall d’Hebron implements Olea Medical clinical software solutions
25th, May 2010 - Barcelona, SPAIN
The University Hospital of Vall d'Hebron (Barcelona, Spain) and Olea Medical partner to implement the innovative MR perfusion post-processing software – PerfScape™ & NeuroScape™ designed to make more accurate and faster diagnosis.
As reference center and first user of PerfScape™ & NeuroScape™ in Spain, Vall d'Hebron confirms its leadership in the neurosciences field by using the most advanced imaging technique.
FDA-cleared and CE marked, PerfScape™ & NeuroScape™ instantly display all perfusion and diffusion maps, and quantify infarcted and penumbral tissues in acute stroke patients with nominal input from users.
PerfScape™ & NeuroScape™ offer a fast and effective solution to stroke centers that wish to rely on MRI to evaluate and triage acute stroke patients.
Prof. Rovira stated, "the suite of software brought by Olea Medical as well as the new solutions that will be available in the near future represent a tremendous asset for a radiology department".
Press contact : Marine Pagni
marine.pagni@olea-medical.com - +33 (0)4 42 71 24 20
Massachusetts General Hospital’s Princeton Conference
Olea Medical USA has provided financial support to Massachusetts General Hospital's Princeton Conference that will take place April 22-25, 2010 in Boston, Massachusetts. This educational program is a premier academic conference in the field of cerebrovascular disease.
Mass General and the Director of the Princeton Conference decided upon the topics for the program based on their strategic impact on understanding the underlying mechanisms of stroke and the development of innovative treatments. The planned sessions will include stroke prevention and recovery, neuroimaging, interventional approaches, intracerebral hemorrhage, neuroprotective strategies, and thrombolytic therapies.
Olea Medical USA provides innovative imaging applications that help physicians make fast and accurate diagnosis of acute stroke.
Press contact : Marine Pagni
marine.pagni@olea-medical.com - +33 (0)4 42 71 24 20
Olea Medical and the NIH/NINDS
Olea Medical, the NIH/NINDS and the Stroke Center of La Timone University Hospital in France collaborate to define PWI/DWI thresholds to better assess salvageable penumbral areas.
- La Ciotat, France, November 6th, 2009 – Olea Medical, the NIH National Institute of Neurological Disorders and Stroke (NINDS) Section on Stroke Diagnostics and Therapeutics, and the Stroke Center of La Timone University Hospital in France will collaborate to define efficient thresholds of diffusion and perfusion maps with a view to accurately assessing salvageable penumbral areas.
Olea Medical (www.olea-medical.com) provides innovative imaging software solutions to help stroke physicians make fast and accurate diagnosis of acute stroke. NINDS (www.ninds.nih.gov) is the United States’ primary supporter of biomedical research on the brain and nervous system. As part of this collaboration, NINDS scientists, led by Dr. Steven Warach, will be using PerfScape™ and NeuroScape™, Olea Medical’s FDA-cleared software, in a prospective study comparing mismatch calculations produced with the software of Olea Medical versus qualitative evaluations of mismatch using MRI scanner provided images only.In a proof of concept study, Warach and colleagues reported that processing acute MRI studies is feasible using the Olea software.
About Olea Medical
Olea Medical designs and markets innovative acute stroke imaging applications that significantly improve the diagnosis process of acute stroke. Olea Medical aims to become the leader in providing safe & accurate medical imaging software allowing physicians to make faster and improved diagnosis, thus saving lives. PerfScape™ allows computing instantaneously perfusion maps from raw MRI data with unparalleled quality and not machine-dependent as it works on all MR scanners used in your hospital (Siemens, Philips, Toshiba, GE...). NeuroScape™ makes an instant multiparametric analysis of all series of images given by the MR scanners, and enables physicians to calculate the lesion volume, hypoperfused volume, and the mismatch diffusion/perfusion ratio. For more information about Olea Medical, please visit www.olea-medical.com
About the NIH – NINDS
The National Institute of Neurological Disorders and Stroke (NINDS) conducts and supports research on brain and nervous system disorders. Created by the U.S. Congress in 1950, NINDS is one of the more than two dozen research institutes and centers that comprise the National Institutes of Health (NIH). The NIH, located in Bethesda, Maryland, is an agency of the Public Health Service within the U.S. Department of Health and Human Services. NINDS has occupied a central position in the world of neuroscience for more than 50 years. The mission of NINDS is to reduce the burden of neurological disease - a burden borne by every age group, by every segment of society, by people all over the world. For more information about the mission and activities of NINDS, see the NINDS Overview, please visit : www.ninds.nih.gov
Press contact : Marine Pagni
marine.pagni@olea-medical.com - +33 (0)4 42 71 24 20